Senior VP and Head, Global Clinical Development, CMO, Merck
Interim Director, Yale Center for Immuno-Oncology, Yale Univ.
Sr. Scientific Director, Clinical Translational Modeling, Takeda
Lab Head, Oncology-Pharmacology, Sanofi
VP, Cell Therapy Franchise, Juno Therapeutics, a Bristol Myers Squibb Co.
Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
Director, Oncology Research and Immuno-Monitoring Core (ORION), Univ. of Texas MD Anderson Cancer Center
Howard L. Kaufman
Head, R&D, Immuneering; Massachusetts General Hospital
Director, Immunology & Immunotherapy, Mayo Clinic
Clinical Director, Genitourinary Malignancies Branch, NCI NIH
CSO, Sensei Biotherapeutics
David A. Reardon
Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
Chief, Laboratory of Basic Immunology, Providence Health & Services
Professor, Pathology, Immunology, Univ. of Pittsburgh School of Medicine
Head, Search & Evaluation, Novartis
About the Immuno-Oncology Summit
Over the past 8 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year,
we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest developments in immuno-oncology, while providing access to a comprehensive 3-day program and extensive networking
opportunities that CHI's IO Summit provides.